株式会社PRISM BioLab Logo

株式会社PRISM BioLab

A biotech creating novel drugs by targeting previously "undruggable" protein interactions.

206A | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
藤沢市村岡東二丁目26番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PRISM BioLab is a biotechnology company dedicated to creating novel small molecule drugs for diseases that currently lack effective treatments. The company's core is its proprietary PepMetics® drug discovery platform, which enables the targeting of previously "undruggable" proteins. This technology utilizes unique small molecule scaffolds that mimic peptide structures (α-helices and β-turns) to control protein-protein interactions (PPIs), a key cause of many diseases. By making these challenging targets accessible, PRISM BioLab aims to pioneer new therapies and collaborates with pharmaceutical companies to advance its drug discovery programs.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for 株式会社PRISM BioLab and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-17 09:30
Major Shareholding Notification
臨時報告書
Japanese 21.0 KB
2025-05-14 09:31
Registration Form
確認書
Japanese 8.7 KB
2025-05-14 09:30
Interim Report
半期報告書-第14期(2024/10/01-2025/09/30)
Japanese 224.7 KB
2024-12-27 07:34
Regulatory News Service
内部統制報告書-第13期(2023/10/01-2024/09/30)
Japanese 22.2 KB
2024-12-27 07:33
Registration Form
確認書
Japanese 8.7 KB
2024-12-27 07:32
Annual Report
有価証券報告書-第13期(2023/10/01-2024/09/30)
Japanese 3.1 MB
2024-12-27 07:31
Post-Annual General Meeting Information
臨時報告書
Japanese 22.1 KB
2024-11-14 07:32
Regulatory News Service
臨時報告書
Japanese 20.8 KB
2024-10-16 10:12
Major Shareholding Notification
臨時報告書
Japanese 20.7 KB
2024-09-10 09:09
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2024-06-24 08:00
Prospectus
訂正有価証券届出書(新規公開時)
Japanese 2.2 MB
2024-06-14 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.3 MB
2024-05-27 08:00
Registration Form
有価証券届出書(新規公開時)
Japanese 4.3 MB

Automate Your Workflow. Get a real-time feed of all 株式会社PRISM BioLab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for 株式会社PRISM BioLab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany 27N0
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany HIGH
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea 214370
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Celemics, Inc. Logo
Develops custom NGS panels and bioinformatics for research and clinical diagnostics.
South Korea 331920
Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.
South Korea 308430
CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea 049960
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea 299660

Talk to a Data Expert

Have a question? We'll get back to you promptly.